Salvage focal cryosurgery may delay use of androgen deprivation therapy in cryotherapy and radiation recurrent prostate cancer patients

Figures & data

Table 1. Focal salvage cryotherapy patient demographics.

Variable	Value
Total number of patients, N	65
Age, median (IQR), years	71.0 (65.0–74.3)
Prostate volume (range), ml	27.7 (9.5–67.1)
Pre-Salvage cryosurgery gleason score (%)
3 + 3	11 (16.9)
3 + 4	10 (15.4)
4 + 3	16 (24.6)
≥4 + 4	17 (26.2)
N/R	11 (16.9)
Follow up, median (range), months	26.6 (8.0–99.0)
Time to BCR, median (range), months	9.0 (1.4–80.3)
Pre-salvage cryosurgery PSA	4.0 (0.01–19.0)
Primary treatment (%)
Cryotherapy	8 (12.3)
Stereotactic radiotherapy (CyberKnife^TM)	5 (7.7)
Brachytherapy	13 (20.0)
Proton beam radiation	1 (1.5)
Radiation (other MODs)	37 (57.0)
Unknown primary treatment	1 (1.5)
Time to salvage cryosurgery, median (range), months	66.0 (16.0–180.0)
Nadir PSA, median (IQR), ng/ml	0.5 (0.1–1.7)

IQR: interquartile range; PSA: prostate specific antigen; BCR: biochemical recurrence; MOD: mode of delivery.

Figure 1. Biochemical recurrence-free survival analysis and Cox regression analysis between patients with (0) no prior history of ADT, (1) neoadjuvant prior to salvage focal cryotherapy, and (2) adjuvant hormones at time of primary treatment. The Cox regression table rules out prior ADT history as a potential confounder of biochemical recurrence. HR: hazards ratio.

Figure 2. Overall biochemical recurrence-free survival analysis of the entire study cohort.